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Background and purpose: Cerebral microbleeds (CMBs), cortical superficial sidero-
sis, white matter lesions (WML), and cerebral atrophy may signify greater bleeding risk 
particularly in patients in whom anticoagulation is to be considered. We investigated 
their prevalence and associations with stroke type in patients with stroke and atrial 
fibrillation (AF).
Materials and Methods: Cross-sectional sample, Monash Medical Centre (Melbourne, 
Australia) between 2010 and 2013, with brain MRI. MRI abnormalities were rated using 
standardized methods. Logistic regression was used to study associations adjusting for 
age and sex.
results: There were 170 patients, mean age 78  years (SD 9.8), 154 (90.6%) with 
ischemic stroke. Prevalence of MRI markers were any microbleed 49%, multiple (≥2) 
microbleeds 30%, confluent WMLs 18.8%, siderosis 8.9%, severe cerebral atrophy 
37.7%. Combinations of the severe manifestations of these markers were much less 
prevalent (2.9–12.4%). Compared with ischemic stroke, those with hemorrhagic stroke 
were more likely to have ≥10 microbleeds (OR 5.50 95% CI 1.46–20.77, p = 0.012) 
and siderosis (OR 6.24, 95% CI 1.74–22.40, p = 0.005). Siderosis was associated with 
multiple microbleeds (OR 8.14, 95% CI 2.38–27.86, p = 0.001). Patients admitted with 
hemorrhagic stroke and multiple microbleeds were more frequently anticoagulated prior 
to stroke (6/7, 85.7%) than in those with single (1/2, 50%) or no microbleeds (4/7, 57%).
conclusion: Multiple CMBs, severe WML, and severe cerebral atrophy were common 
individually in hospitalized patients with stroke and AF, but less so in combination. 
A higher burden of CMBs may be associated with intracerebral hemorrhage in stroke 
patients with AF.
Keywords: atrial fibrillation, stroke, microbleeds, Mri
Abbreviations: AF, atrial fibrillation; CMB, cerebral microbleed; cSS, cortical superficial siderosis; ICH, intracerebral 
 hemorrhage; WML, white matter lesions.
FigUre 1 | (a) T2 weighted axial MRI of the brain showing severe cerebral atrophy [Grade 4 rating using a published reference template (31)] with sulcal widening 
(red arrow). (B) Axial MRI of the brain demonstrating a linear gyriform hypointensity (red arrow) on SWI sequence in a cortical distribution representative of superficial 
siderosis. (c) T2 FLAIR weighted MRI showing large confluent lesions (red arrow) with a Fazekas 3 rating as described in the Section “Materials and Methods.” (D) 
SWI MIP sequence MRI of the brain showing multiple diffuse microbleeds (red arrow). Microbleeds were assessed using the validated Brain Observer Microbleed 
Scale (BOMBs) criteria as discussed in the Section “Materials and Methods.”
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inTrODUcTiOn
Atrial fibrillation (AF) is a common and important risk fac-
tor for stroke in older people (1). Anticoagulation is a highly 
effective therapy for secondary prevention in patients with AF 
and previous ischemic stroke (2), but many such patients are 
not treated for fear of intracerebral hemorrhage (ICH) (3). 
Although there are clinical tools that can be used to predict 
overall bleeding risk (4), they do not incorporate the presence 
of relevant brain lesions that may heighten risk. Abnormalities 
on brain MRI, such as cerebral microbleeds (CMBs), corti-
cal superficial siderosis (cSS), confluent white matter lesions 
(WML), and cerebral atrophy (Figure 1), are commonly seen 
in older people in the general population, attending memory 
clinics, and with stroke (5–8). A greater burden of such 
abnormalities may signify a greater future risk of ICH, when 
considering anticoagulation, although small sample sizes and 
suboptimal study designs have left uncertainty regarding this 
issue (9–12).
Cerebral microbleeds are small hypointense lesions vis-
ible on susceptibility weighted imaging (SWI) or gradient echo 
(GRE) MRI sequences, representing hemosiderin deposits (13). 
Multiple lobar CMBs are associated with cerebral amyloid angi-
opathy, while infratentorial or deep CMBs are associated with 
cardiovascular risk factors, such as hypertension (8, 14). CMBs 
are associated with an increased risk of hematoma expansion in 
patients with ICH (15) and may also increase the risk of ICH in 
patients receiving antiplatelet drugs (16, 17) or thrombolysis (18). 
CSS is caused by repeated clinical or subclinical bleeding into the 
cortical subarachnoid space leading to hemosiderin deposition 
(13) and is visible on SWI or GRE sequences (Figure 1). It is asso-
ciated with cerebral amyloid angiopathy (19) and an increased 
risk of ICH (9). Age-related WML are ubiquitous in older people, 
are associated with a history of hypertension (20), and are closely 
associated with the presence of CMBs in adults aged over 40 years 
(21). A large burden of WML (confluent WML) is associated 
with physical and cognitive frailty (22), predicting mortality after 
ICH (23) and spontaneous ICH (24). WML are best identified 
as hyperintensities on FLAIR sequences as hyperintense lesions 
(25). Cerebral atrophy is associated with cognitive impairment in 
patients with stroke (26, 27), may indicate cognitive frailty, and 
thus be a proxy marker for unfavorable outcome after spontane-
ous ICH (11).
Although there are published data on the prevalence of each of 
these MRI markers in isolation, it is unclear how commonly they 
coexist in patients with stroke and AF. We sought to evaluate the 
prevalence of these MRI abnormalities in a hospital-based sample 
with stroke and AF, their relationships with each other, and with 
stroke type (hemorrhagic versus ischemic).
MaTerials anD MeThODs
sample ascertainment
This was a cross-sectional study with retrospective ascertainment 
of data. The sample consisted of patients with stroke admitted to the 
Stroke Unit at the Monash Medical Centre, Melbourne, Australia 
between October 2010 and October 2013. The hospital electronic 
record system was used to identify patients 18 years or older, with 
confirmed AF diagnosed based on ECG, Holter monitoring, or 
documented medical diagnosis, and with MRI performed as part 
of their diagnostic work-up within 4 months of the index stroke 
event. Ethics approval was granted by the Monash University 
Health and Medical Research Ethics Committee and the Monash 
Health Research Directorate. Individual informed consent was 
not required because the project was deemed low-risk given the 
retrospective design, use of routinely collected medical informa-
tion, and the de-identified reporting of aggregated results.
Mri Measures
A fellowship trained neuroradiologist with 6  years of experi-
ence in MR imaging, who was blinded to clinical details, rated 
all MRI scans for acute or previous stroke, CMBs, cSS, WML, 
and cerebral atrophy. CMBs were assessed on SWI sequence and 
then rated using the validated Brain Observer Microbleed Scale 
(BOMBs) criteria (28). The BOMBs scale provides a measure of 
the number of microbleeds, the size of each (<5 or 5–10 mm), 
and the location within the brain and brainstem (28). We defined 
cSS as a linear gyriform hypointensity on SWI sequence in a 
cortical distribution without corresponding hyperintense signal 
on FLAIR or T1 weighted sequences (7, 29). FLAIR sequences 
were reviewed to identify and rate WML using the Fazekas scale 
as mild, moderate, or severe (confluent) lesions (30). Cerebral 
360 patients between October
2010 and October 2013 with 
stroke and atrial fibrillation
182 patients with MRI brain
scans 
178 patients excluded due to absence of 
MRI
170 patients with MRI scans 
included in study
12 patients excluded due to absence of 
SWI/FLAIR/T2 sequences
FigUre 2 | Flow diagram of sample ascertainment.
TaBle 1 | sample characteristics – all figures reported are n (%), unless otherwise specified.
Variable included (n = 170) excludeda (n  = 190) p value
Mean age 77.7 years (SD 9.81) 80.9 years (SD 9.93) 0.0022
Female sex 80 (47.0) 99 (52.1) 0.34
Current smoker 64 (37.7) 54 (28.4) 0.063
Hypertension 157 (92.4) 173 (91.0) 0.66
Dyslipidemia 116 (68.2) 125 (67.8) 0.62
Ischemic heart disease 89 (52.4) 119 (62.6) 0.049
Diabetes mellitus 45 (26.5) 49 (25.8) 0.88
Pre-admission antiplatelet therapy 95 (55.9) 97 (51.0) 0.36
Pre-admission anticoagulation therapy 57 (33.5) 70 (36.8) 0.51
Pre-admission combined therapy 6 (3.5) 8 (4.2) 0.74
Ischemic stroke 154 (90.6) 163 (85.8) 0.11
Hemorrhagic stroke 16 (9.4) 27 (14.2)
Systolic BP ≥160 mmHgb 92 (54.1) 94 (49.5) 0.26
CHADS2 3.1 points (SD 1.3) 3.4 points (SD 1.3) 0.016
90-day modified Rankin Scale ≥3 65 (38.2) 138 (72.6) <0.001
aExcluded due to lack of MRI or failed/inadequate MRI.
bSystolic BP ≥160 mmHg on admission.
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atrophy was rated using a published reference template (31), and 
severe atrophy was defined as >75th percentile for that patient’s 
age-group based on the template.
Other Measures
Additional information gathered included age, sex, date of birth, 
cardiovascular risk factors, the use of anticoagulation therapy, or 
antiplatelet therapy prior to stroke and international normalized 
ratio (INR) level if applicable.
statistical analysis
Prevalence proportions of each type of MRI abnormality and 
combinations of MRI abnormalities were estimated. Chi-square 
and t-tests were used for comparison of categorical or continuous 
variables. Logistic regression was used to study associations of 
MRI abnormalities with each other and with ICH (compared 
with ischemic stroke), adjusting for age and sex.
resUlTs
During the study period, a total of 360 patients with stroke 
and AF were identified. Of these, 178 were excluded due to 
MRI not being performed. This was either due to death before 
4  months or because institutional protocols did not demand 
compulsory acute or follow-up MRI in all patients, with CT 
brain and perfusion imaging being the preferred acute imag-
ing modality. A further 12 patients were excluded because 
SWI sequence was not available or was degraded, leaving 170 
patients included in the final analysis (Figure 2). The mean age 
of the sample was 78 years (SD 9.8), and 53% were males. There 
were 154 (90.6%) patients with ischemic strokes and 16 (9.4%) 
with ICH (Table 1). The median delay from stroke event to MRI 
scan was 13 days. Patients who did not undergo MRI were older 
on average, with a higher 90-day modified Rankin Scale score 
and CHADS2 score, and were more likely to have a diagnosis of 
ischemic heart disease (Table 1) but were similar with respect 
to sex, other cardiovascular risk factors, stroke type, antiplatelet, 
and anticoagulant use.
Prevalence proportions of individual MRI markers in the sam-
ple were as follows: any CMB 49% (lobar distribution in 94% of 
patients with CMB), multiple (≥2) CMBs 30%, confluent WML 
18.8%, cSS 8.9%, and severe atrophy 37.7%. The proportions of 
patients who had CMBs together with other markers ranged from 
4.1 to 20.0% (Table 2), depending on the combination. Among 
patients with ischemic stroke, 6.5% (n = 10) were found to have 
cSS, only one of whom had a known clinical history of ICH. The 
proportions of patients with coexistent severe manifestations of 
the markers were relatively low (2.9–12.4%) (Table 2). Adjusting 
for age and sex, the presence of siderosis was strongly associated 
with multiple CMBs (OR 4.85, 95% CI 1.15–20.45, p = 0.031). Of 
the 11 patients with both multiple CMBs and cSS, all had lobar 
CMBs, while only 4 had deep CMBs.
FigUre 3 | (a) T2 FLAIR axial MRI of the brain showing right-sided ICH and 
acute bleeding (red arrows). (B) SWI sequence MRI of the same patient 
demonstrating a linear gyriform hypointensity in a cortical distribution (red 
arrow), representative of siderosis, in a region independent to that of the site 
of hemorrhage.
TaBle 3 | association of Mri markers with stroke type.
Mri marker Odds ratio for ich (95% ci) p value
CMB ≥2 1.80 (0.62, 5.83) 0.28
CMB ≥5 2.82 (0.80, 9.93) 0.11
CMB ≥10 5.50 (1.46, 20.77) 0.012
cSS 6.24 (1.74, 22.40) 0.005
Confluent WML 0.95 (0.24, 3.73) 0.95
Severe atrophy 0.62 (0.19, 2.03) 0.43
CMB ≥2 and cSS 4.85 (1.15, 20.45) 0.031
TaBle 2 | Prevalence of Mri abnormalities in sample.
Mri marker all (n = 170) ischemic stroke (n = 154) ich (n = 16)
in isolation N (%)
Any CMB 83 (49.0) 74 (48.0) 9 (56.3)
Multiple CMB (≥2, mCMB) 51 (30.0) 44 (28.6) 7 (43.8)
cSS 15 (8.9) 10 (6.5) 5 (31.3)
Confluent WML 32 (18.8) 29 (18.8) 3 (18.8)
Severe atrophy 64 (37.7) 59 (38.3) 5 (31.3)
CMB + cSS 11 (6.5) 7 (4.5) 4 (25.0)
mCMB + cSS 11 (6.5) 7 (4.5) 4 (25.0)
CMB + severe atrophy 34 (20.0) 30 (19.5) 4 (25.0)
mCMB + severe atrophy 21 (12.4) 18 (11.7) 3 (18.8)
CMB + confluent WML 21 (12.4) 19 (12.3) 2 (12.5)
mCMB + confluent WML 15 (8.8) 13 (8.4) 2 (12.5)
Confluent WML + severe atrophy 14 (8.2) 14 (9.1) 0 (0.0)
CMB + confluent WML + severe atrophy 7 (4.1) 7 (4.5) 0 (0.0)
mCMB + confluent WML + severe atrophy 5 (2.9) 5 (3.2) 0 (0.0)
CMB + confluent WML + severe atrophy + cSS 0 (0.0) 0 (0.0) 0 (0.0)
CMB, cerebral microbleed; mCMB, multiple cerebral microbleeds (≥2 microbleeds); cSS, cortical superficial siderosis; WML, white matter lesions.
4
Karayiannis et al. Prevalence of MRI Bleeding Markers
Frontiers in Neurology | www.frontiersin.org September 2016 | Volume 7 | Article 151
In unadjusted comparisons between those with ischemic 
stroke and ICH (Table 3), the proportions of patients with any 
CMBs, multiple CMBs, confluent WML, and severe atrophy 
were similar between groups (p > 0.05), whereas cSS was more 
prevalent in those with ICH (p = 0.001). Adjusting for age and 
sex, there was no significant association between ICH and the 
presence of CMB (OR 1.29, 95% CI 0.44–3.75, p =  0.64). But 
the strength of the association between ICH and CMB increased 
with the burden of CMBs with OR 1.80 (95% CI 0.62–5.83, 
p = 0.28) in those with ≥2 CMBs, OR 2.82 (95% CI 0.80–9.93, 
p = 0.107) in those with ≥5 CMBs, and OR 5.50 (95% CI 1.46–
20.77 p = 0.012) in those with ≥10 CMBs. ICH was significantly 
associated with the presence of cSS (OR 6.24, 95% CI 1.74–22.40, 
p = 0.005). In all cases of cSS within patients suffering ICH, cSS 
was not only present in relation to the location of the index 
clinical bleed but also in areas distant to the index bleed and in 
the contralateral hemisphere (Figure 3). ICH was not associated 
with either the presence of confluent WML (OR 0.95, 95% CI 
0.24–3.73 p = 0.95) or severe cerebral atrophy (OR 0.62, 95% CI 
0.19–2.03, p = 0.43).
In the whole sample, 57/170 (33.5%) patients were antico-
agulated prior to stroke, more so in those presenting with ICH 
(11/16, 68.8%) than in those with ischemic stroke (47/154, 
30.5%, p = 0.002). On the other hand, 95/170 (55.9%) received 
antiplatelet therapy prior to stroke, more so in those presenting 
with ischemic stroke (93/154, 60.4%) than in those with ICH 
(2/16, 12.5%, p < 0.001). Of the five patients with ICH and cSS, 
three were on anticoagulants prior to stroke with INRs ranging 
from 2.9 to 3.7, and none were on antiplatelet therapy. Among 
patients with ICH, prior anticoagulant use was more common in 
those with mCMBs (6/7, 85.7%) than in those with single (1/2, 
50%) or no CMB (4/7, 57%), but these comparisons did not reach 
statistical significance (p = 0.3).
DiscUssiOn
In this study, we present data on the prevalence of several MRI 
markers that may predict risk of future ICH in patients with 
stroke and AF. We found that CMBs, severe WML, and cerebral 
atrophy were each highly prevalent in this sample, whereas the 
prevalence proportions for cSS and for combinations of markers 
were less common. The presence of cSS was strongly associated 
with the presence of multiple CMBs. In our study, patients with 
AF and ICH more often had cSS and a higher burden of CMBs 
than those with AF and ischemic stroke.
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Our data are unique in providing prevalence estimates of MRI 
markers of vascular brain disease individually and together in 
a sample of patients with stroke and AF. Previous studies have 
reported on the frequency of such MRI markers individually and 
in various types of samples, including patients with stroke. In a 
recent comprehensive review, it was reported that the prevalence 
of CMBs ranged from ~18 to ~68% in patients with ischemic 
stroke (32). Our estimates (~50%) fall broadly within this range. 
Prevalence estimates of cSS in this patient group have not been 
reported previously. In our sample, cSS was more prevalent in 
patients admitted for ICH, strongly related to the presence of 
multiple CMBs, consistent with studies of the general population 
and memory clinic patients (7, 33). We also found that cSS was 
present at sites both related and unrelated to the index bleed. 
Therefore, it is possible that patients with stroke and AF who have 
imaging evidence of cSS may be at high risk of bleeding from 
anticoagulation therapy, and this needs further clarification.
Patients with a history of ischemic stroke and AF are at high 
risk for developing recurrent stroke. There is no consensus cur-
rently on what approach should be taken in such patients who 
have cSS and mCMBs on MRI, but data from larger samples may 
contribute to risk stratification algorithms that have been pro-
posed (34). In our sample, ~7% of patients with ischemic stroke 
and AF also showed evidence of prior cSS, despite an absence of 
history of ICH in all but one patient. In one series of patients with 
cSS and probable cerebral amyloid angiopathy, as many as 50% of 
patients went on to develop future ICH within 3 years (35).
The combination of multiple CMBs and cSS may signify a par-
ticularly high risk of ICH. In our sample, ~20% of patients with 
ICH had both cSS and multiple CMBs, suggesting the presence 
of cerebral amyloid angiopathy (19). All such patients had lobar 
CMBs, supporting this contention. There is emerging evidence 
that patients with ischemic stroke and the presence of CMBs who 
undergo thrombolysis may be at ~2-fold increased risk of ICH 
(36). Our data, although cross-sectional, provide some evidence 
to suggest that an increasing burden of CMBs may be related to 
the risk of ICH, and the presence of a threshold effect may be 
worth exploring in prospective studies of patients with stroke and 
AF requiring anticoagulation. Confluent WML and severe corti-
cal atrophy were relatively common in keeping with such an older 
sample with cerebrovascular disease. Although their prevalence 
was not markedly different between patients with ischemic stroke 
and ICH, it would still be of interest to see whether they predict 
risk of future ICH independent of CMBs, or whether the cumula-
tive presence of all such markers (although relatively uncommon) 
indicates a greater risk of ICH in the setting of anticoagulation.
The main strength of this study is that it examines a clinically 
relevant high-risk sample for cardioembolic stroke. Additionally, 
the radiological ratings were performed blinded to clinical details. 
There were certain limitations. The sample was relatively small, 
and there were few patients with ICH, compared to ischemic 
stroke. Therefore, study results are more generalizable to patients 
with ischemic stroke and AF, than to those with ICH and AF. 
Furthermore, the retrospective and cross-sectional design did not 
allow an estimation of future risk of ICH in patients. The lack of 
MRI in some eligible patients renders our prevalence estimates 
open to the effect of selection bias, and it is likely that we under-
estimated prevalence given the older age of the excluded sample. 
Given the retrospective nature of the study, we did not have 
MRI routinely at stroke onset or prior to stroke, but a median of 
13 days after stroke. This is unlikely to affect estimates of the MRI 
markers, which are usually chronic lesions. Furthermore, many 
of our patients were anticoagulated prior to stroke event. Given 
the cross-sectional and retrospective nature of data collection, 
it is possible that some CMBs may have developed after com-
mencement of anticoagulation. Therefore, we cannot draw strong 
conclusions about the predictive utility of CMBs by themselves 
for the risk of ICH in patients with stroke and AF independent of 
anticoagulation. This issue can only be confirmed in prospective 
studies of patients who are not on anticoagulant therapy.
cOnclUsiOn
Our study suggests that multiple CMBs, severe WML, and severe 
cerebral atrophy were common individually in hospitalized 
patients with stroke and AF, but less so in combination. There 
were differences in prevalence of these imaging markers between 
ischemic and hemorrhagic stroke, with patients with ICH more 
often having multiple CMBs and cSS.
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